Blockbuster ambitions: Amgen/Novartis team lines up more promising PhIII erenumab data for some of the toughest migraine patients
Amgen $AMGN and its Big Pharma brethren at Novartis $NVS have lined up another happy ending for the latest chapter on the marketing pitch being lined up for their pioneering CGRP migraine med.
Their drug Aimovig (erenumab) scored well in a study that recruited some of the toughest patients in the world of migraine sufferers; men and women whose persistent migraines have resisted multiple lines of therapy.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.